Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer
Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma
Sranan Gold Announces Participation in Upcoming 121 Mining Investment London and Swiss Mining Institute Conferences
Standard Uranium Announces Filing of NI 43-101 Technical Report on the Corvo Uranium Project, Northern Saskatchewan
NorthStar Gaming Launches "The Boost" to Unlock New Revenue Streams and Accelerate Business Performance
